- Home
- BIAF
as 07-05-2024 4:00pm EST
bioAffinity Technologies Inc addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. It develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. The company's product, CyPath Lung, is a noninvasive test for the detection of early-stage lung cancer.
| Founded: | 2014 | Country: | United States |
| Employees: | N/A | City: | SAN ANTONIO |
| Market Cap: | 22.7M | IPO Year: | 2022 |
| Target Price: | N/A | AVG Volume (30 days): | 61.9K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.92 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.95 - $3.62 | Next Earning Date: | 08-12-2024 |
| Revenue: | $4,937,969 | Revenue Growth: | 86182.88% |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest bioAffinity Technologies Inc. News
BIAF Breaking Stock News: Dive into BIAF Ticker-Specific Updates for Smart Investing
ACCESSWIRE
a day ago
BioVie and bioAffinity Technologies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
Business Wire
25 days ago
bioAffinity Technologies Reports Accelerating Growth of Physician Practices Ordering CyPath® Lung Tests
Business Wire
2 months ago
bioAffinity Technologies Reports Record Q1 Revenue Driven by Accelerating Growth of CyPath® Lung Sales and Increased Laboratory Volumes
Business Wire
2 months ago
bioAffinity Technologies News Update
Business Wire
2 months ago
bioAffinity Technologies Advances New Product Development Initiatives to Accelerate Next Phase of Growth
Business Wire
3 months ago
bioAffinity Technologies Expands Campaign to Support American Cancer Society Initiative for Lung Cancer Screening
Business Wire
3 months ago
bioAffinity Technologies Reports Fourth Quarter and Full Year 2023 Financial Results
PR Newswire
4 months ago
Wallachbeth Capital Announces Closing of bioAffinity Technologies $2.5 Million Registered Direct Offering and Concurrent Private Placement
Share on Social Networks:
Disclaimer
The information presented on this page, "BIAF bioAffinity Technologies Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.